Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab


Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials

Read more:
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab

Related Posts